KalVista Pharmaceuticals Inc. recently announced the presentation of new data at the European Academy of Allergy and Clinical Immunology Congress 2025 in Glasgow, United Kingdom. The data focus on the efficacy of sebetralstat for the on-demand treatment of hereditary angioedema $(HAE)$ attacks among patients receiving long-term prophylaxis. The KONFIDENT-S study highlighted the challenges of adherence to long-term prophylaxis and the need for effective on-demand treatments. Results showed that oral sebetralstat provided rapid relief for breakthrough attacks, with a median time to symptom relief of 1.3 hours. These findings were presented at the congress, indicating the potential of sebetralstat as a complementary treatment to existing long-term prophylaxis options. Links to the presentations are available on the KalVista website under Publications.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。